Charles A. Rowland Jr., Director at Blueprint Medicines Corp (BPMC), sold 19,900 shares at $99.10 ($2.0M) on 2020-11-03, disclosed to the SEC on 2020-11-04.
Open-market sale of $2.0M BPMC by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $99.11 | 4,478 | $444K | 22.6% |
| 2 | $99.11 | 4,478 | $444K | 22.6% |
| 3 | $95.97 | 694 | $67K | 3.4% |
| 4 | $95.97 | 694 | $67K | 3.4% |
| 5 | $99.10 | 4,728 | $469K | 23.8% |
| 6 | $99.10 | 4,728 |
| $469K |
| 23.8% |
| 7 | $100.48 | 100 | $10K | 0.5% |
| Total | $98.89 avg | 19,900 | $2.0M | 100% |
| Filing → |
| VKTX | SELL | 2023-05-18 | $1.0M | — | Filing → |
| GBIO | BUY | 2022-09-20 | $83K | — | Filing → |
| GBIO | BUY | 2022-09-19 | $552K | — | Filing → |